Nathaniel Calloway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing...

/PRNewswire/ -- EBONY Media, the leading voice of the Black American experience committed to "Moving Black Forward," has announced the launch of EBONY Studios,...

Investegate announcements from Edison Investment Research Lim, Exopharm (EX1): Initiation - All the parts for drug delivery development

DJ Exopharm (EX1): Initiation - All the parts for drug delivery development Edison Investment Research Limited Exopharm (EX1): Initiation - All the parts for drug delivery development 31-May-2021 /

Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison Group Much of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE study, and the company believes that it can dedicate significant resources to the EVT801 program. The report also flagged a peak penetration of 15% and with the expectation of initial commercialisation in 2028. Kazia Therapeutics Ltd’s (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the compa...